Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrow

International Journal of Hematology

Volumn 80, Issue 2, 2004, Pages 146-154

  Saberwal, Gurveen ^a,c   Lucas, Steven ^b   Janssen, Imke ^a   Deobhakta, Avnish ^a   Hu, Wen Yang ^a   Galili, Naomi ^a   Raza, Azra ^a   Mundle, Suneel D ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Apoptosis; E2F1 transcription factor; Human disease; Myelodysplastic syndromes; Rb

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1;

APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

AGED; BONE MARROW CELLS; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; FEMALE; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REFERENCE VALUES; RETINOBLASTOMA PROTEIN; S PHASE; TETRAHYDROFOLATE DEHYDROGENASE; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 4444269789     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.NA0303     Document Type: Article

References (34)

1. Mundle SD, Mativi BY, Cartlidge JD, et al. Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1. Br J Haematol. 2000;109:376-381.
2. Hibner U, Coutinho A. Signal antonymy: a mechanism for apoptosis induction. Cell Death Differ. 1994;1:33-37.
3. White E. Tumour biology: p53, guardian of Rb. Nature. 1994;371: 21-22.
4. Jonveaux P, Fenaux P, Quiquandon I, et al. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene. 1991;6:2243-2247.
5. Preudhomme C, Vachee A, Lepelley P, et al. Inactivation of retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. Br J Haematol. 1994;87:61-67.
6. Padua RA, Guinn BA, Al Sabah AI, et al. RAS, FMS, and p53 mutations and poor clinical outcome in myelodysplasia: 10 year follow-up. Leukemia. 1998;12:887-892.
7. Dyson N. The regulation of E2F1 by pRb-family proteins. Genes Dev. 1998;12:2245-2262.
8. Trimachi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3:11-20.
9. Shan B, Lee W-H. Deregulated expression of E2F1 induces S-phase entry and leads to apoptosis. Mol Cell Biol. 1994;14: 8166-8173.
10. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A. 1997;94:7245-7250.
11. Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev. 1997;11:1853-1863.
12. Hunt KK, Deng J, Liu TJ, et al. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res. 1997;57:4722-4726.
13. Müller H, Bracken AP, Vernell R, et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 2001;15:267-285.
14. 2/M checkpoints. Genes Dev. 2002;16:245-256.
15. Katsuda K, Kataoka M, Uno F, et al. Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. Oncogene. 2002;21: 2108-2113.
16. Hateboer G, Kerkhoven RM, Shvarts A, Bernards R, Beijersbergen RL. Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev. 1996;10:2960-2970.
17. Hofman F, Martelli F, Livingston DM, Wang Z. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev. 1996;10:2949-2959.
18. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001;10:699-703.
19. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumors: E2F1 is upregulated in small cell lung carcinoma. Oncogene. 2001;20:1678-1687.
20. Johnson DG. The paradox of E2F1: oncogene and tumor suppressor gene. Mol Carcinog. 2000;27:151-157.
21. Wikonkal NM, Remenyik E, Knezevic D, et al. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice. Nat Cell Biol. 2003;5:655-660.
22. Leone G, Sears R, Huang E, et al. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell. 2001;8:105-113.
23. Kotelnikov VM, Coon JS, Mundle S, et al. Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res. 1997;3: 95-101.
24. Field SJ, Tsai FY, Kuo F, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 1996;85:549-561.
25. Bargou RC, Wagener C, Bommert K, et al. Blocking the transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell-line efficiently inhibits apoptosis and induces tumor growth in SCID mice. J Exp Med. 1996;183:1205-1213.
26. Moroni MC, Hickman ES, Denchi EL, et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol. 2001;3:552-558.
27. Luciakova K, Barath P, Li R, Zaid A, Nelson BD. Activity of the human cytochrome c1 promoter is modulated by E2F. Biochem J. 2000;351:251-256.
28. Yang HL, Dong YB. Elliott MJ, Liu TJ, McMasters KM. Caspase activation and changes in Bcl-2 family member protein expression associated with E2F-1-mediated apoptosis in human esophageal cancer cells. Clin Cancer Res. 2000;6:1579-1589.
29. Giovanni A, Keramaris E, Morris EJ, et al. E2F1 mediates death of B-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase-3. J Biol Chem. 2000;275: 11553-11560.
30. Mundle SD, Raza A. Defining the dynamics of self-assembled Fasreceptor activation. Trends Immunol. 2002;23:187-194.
31. Wang S, Nath N, Minden A, Chellappan S. Regulation of Rb and E2F1 by signal transduction cascade: divergent effects of JNK1 and p38 kinases. EMBO J. 1999;8:1559-1570.
32. Mundle SD. Apoptosis in MDS: a new perspective. In: Raza A, Mundle S, eds. Myelodysplastic Syndromes and Secondary Acute Myelogenous Leukemia: Directions for the New Millennium. Boston, Mass: Kluwer; 2001:101-110.
33. Hoffman R, Fitting P, Preisler H, et al. Analysis of primitive hematopoietic progenitor cells in myelodysplastic disorders [abstract]. Blood. 1998;92:417a. Abstract 1724.
34. Mundle, S, Hsu W-T, Dutt D, et al. Assessment of apoptosis in relation to single cytogenetic abnormalities in myelodysplastic syndromes (MDS) [abstract]. Blood. 2001;98:191b. Abstract 4464.